Synarc, Inc. Appoints Ali Guermazi, M.D. as Scientific Director, Oncology Services

Ali Guermazi, M.D. has been appointed Scientific Director, Oncology Services at Synarc, Inc. In this capacity, Dr. Guermazi will provide broad scientific and operational support for Oncology trials. Dr. Guermazi has demonstrated his scientific leadership in oncology with numerous published articles and book edits on Hematological Malignancies including Lymphoma, Leukemia and Myeloma. He is currently working on a second book on Kidney Cancer. Since Dr. Guermazi started working for Synarc in November 2002, he has collaborated with research scientists at Synarc and other leading institutions. His efforts have lead to the publication of 15 articles summarizing original scientific contribution. These publications also serve to promote Synarc's scientific leadership internationally. In addition to serving as Scientific Director, Dr. Guermazi will retain his current role as Director of Clinical Research in Radiology Services and will continue to provide medical reading services for our ongoing trials.

Synarc enables its clients to demonstrate the efficacy of new therapies across a broad range of therapeutic areas through highly specialized medical imaging and molecular marker techniques. Synarc is the world's largest Central Radiology service dedicated exclusively to global clinical trials for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to improve the quality, economy and speed of the clinical trials through medical and scientific expertise, synergistic partnerships, regulatory discipline, service excellence and innovation.

Synarc was formed in 1999 through a multinational consolidation of service providers into one global company. Synarc started with core expertise in musculoskeletal diseases such as Osteoporosis, Arthritis and Orthopedics, and has now expanded its services across a spectrum of diseases, including cancer, neurological disorders and cardiovascular disease.

Synarc has eight offices around the world and currently manages clinical trials involving more 60,000 patients in over 1,500 sites worldwide. To learn more about Dr. Ali Guermazi or Synarc, please visit our website at www.synarc.com.

For Information Contact:

U.S.
Joy Valderrama
Marketing & Sales Support Specialist
+1.415.817.8919
joy.valderrama@synarc.com

Europe
Jean-Claude Provost
Vice President, Cardiology and Neurology
+33 1 49 66 24 04